Ferroptosis emerges as a promising target in diabetic kidney disease

Recent investigations highlight ferroptosis, an iron-dependent cell death process, as a key mechanism driving diabetic kidney disease progression. Experts suggest that targeting ferroptosis may open new therapeutic avenues beyond current treatments that slow but do not halt renal decline.

A recent review in DovePress argues that ferroptosis, an iron-dependent form of regulated cell death, is emerging as a central mechanism in diabetic kidney disease and may help explain why kidney damage continues even with modern treatment. The review places iron overload, lipid peroxidation and failure of antioxidant defences at the centre of disease progression, while also noting that standard therapies such as blood pressure control, renin-angiotensin system blockade and newer diabetes drugs can slow but not stop renal decline. That residual risk, the authors say, leaves room for therapies that target ferroptosis more directly. The broader kidney literature has reached a similar view, with a Nature Reviews Nephrology article describing ferroptosis as a major contributor to both acute and chronic renal injury.

The review draws a distinction between ferroptosis and other forms of programmed cell death because the process is driven by iron handling, lipid damage and collapse of the glutathione peroxidase 4 defence system, rather than by the pathways that govern apoptosis or pyroptosis. In diabetic kidney disease, the authors say, that matters because abnormal glucose metabolism can increase free iron inside renal cells, raise reactive oxygen species and make membranes more vulnerable to oxidative injury. A separate review in Frontiers in Endocrinology reached the same broad conclusion, describing ferroptosis as a regulated process that is increasingly linked to diabetic kidney injury and possible treatment targets.

Evidence gathered in the DovePress review suggests that renal iron overload is not just a laboratory finding but a consistent feature of diabetic kidney disease in people, animal models and cell studies. The authors cite imaging work showing lower kidney-to-muscle signal intensity ratios on MRI in patients with diabetic kidney disease, which indicates greater iron deposition, along with histological studies showing iron accumulation in diabetic renal tissue. They also point to biomarker data: urinary ferritin appears to rise with disease burden and may reflect early tubular injury, even before albuminuria becomes obvious. The review further notes that genetic and epidemiological analyses support a causal relationship between abnormal iron status and worsening kidney function.

The cellular picture is more complex than simple iron overload. According to the review, podocytes, tubular epithelial cells, mesangial cells and glomerular endothelial cells do not all respond in the same way to ferroptotic stress. Podocytes appear particularly fragile because they have limited capacity to regenerate, and several experimental interventions, including PHGDH overexpression, hirsutine, swietenine and tanshinone IIA, have been reported to reduce podocyte injury by restoring antioxidant pathways or suppressing lipid damage. Tubular cells, meanwhile, are described as a major site of ferroptotic injury, with pathways involving ACSL4, SLC7A11, Nrf2 and vitamin D receptor signalling all implicated.

The review also highlights mesangial and endothelial injury as part of the same process. In mesangial cells, high glucose has been linked to ferroptosis through mechanisms that increase iron uptake and promote extracellular matrix expansion, which may help drive glomerulosclerosis. In glomerular endothelial cells, ferroptosis has been connected to disruption of the filtration barrier, endothelial dysfunction and endothelial-to-mesenchymal transition. Taken together, the authors argue that ferroptosis helps connect the molecular effects of diabetes with the structural changes that define diabetic kidney disease, including proteinuria, fibrosis and declining filtration rate.

One of the most important themes running through the review is that ferroptosis does not act alone. The authors describe a bidirectional relationship with oxidative stress, in which excess reactive oxygen species promote lipid peroxidation and ferroptotic death, while ferroptosis itself worsens mitochondrial dysfunction and further oxidative injury. They also describe a close interaction with inflammation, especially through molecules such as HMGB1, IL-6, Nrf2 and the SLC7A11/GPX4 axis. A review in Frontiers in Endocrinology likewise emphasised that ferroptosis in diabetic kidney disease is embedded in broader inflammatory and oxidative networks rather than operating as an isolated pathway.

Clinically, the review argues that ferroptosis may help explain different diabetic kidney disease phenotypes, including heavy proteinuria, rapid kidney function decline without marked albuminuria and a heightened risk of acute kidney injury on top of chronic disease. The authors cite studies linking higher levels of ferroptosis markers such as ACSL4, malondialdehyde and reactive oxygen species with more severe proteinuria, while lower GPX4 levels track with worse kidney damage. They also describe emerging biomarker candidates, including circulating ferritin, urinary ferritin and circRNAs such as circ-0069561, though they caution that standardisation and prospective validation are still lacking.

Therapeutically, the review is optimistic but careful. It groups candidate approaches into three broad strategies: correcting iron imbalance, strengthening antioxidant defences and dampening inflammation-ferroptosis crosstalk. Some currently used diabetes drugs, particularly SGLT2 inhibitors, appear to do more than lower glucose. The 2026 review in Biomolecules singled out SGLT2 inhibitors as potential ferroptosis-modulating therapies in diabetic kidney disease, while the DovePress paper notes that dapagliflozin and empagliflozin have shown antiferroptotic effects in experimental models. Other proposed interventions include vitamin D-related compounds, natural products such as berberine and quercetin, and stem cell-based approaches, but the authors stress that most evidence remains preclinical.

The main obstacle, the review concludes, is not a lack of biological plausibility but a lack of translation. Most ferroptosis-targeted strategies have been tested only in short-term animal or cell experiments, with limited information on long-term safety, dosing or patient selection. The authors say kidney-specific delivery systems, validated biomarkers and randomised clinical trials will be needed before ferroptosis-based treatment can move from theory to practice. For now, the message from this review and the related literature is clear: ferroptosis looks increasingly important in diabetic kidney disease, but it remains an experimental target rather than a proven clinical one.